Literature DB >> 15155654

Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine.

Hadar Marcus1, Rachel Danieli, Eyal Epstein, Baruch Velan, Avigdor Shafferman, Shaul Reuveny.   

Abstract

Protective antigen (PA)-based vaccination is an effective countermeasure to anthrax infection. While neutralizing anti-PA antibody titers elicited by this vaccine serve as good correlates for protection against anthrax (S. Reuveny, M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan, Infect. Immun. 69:2888-2893, 2001), no data are available on the contribution of the immunological memory for PA itself to protection. We therefore developed a guinea pig model in which a primary immunization with threshold levels of PA can induce a long-term T-cell immunological memory response without inducing detectable anti-PA antibodies. A revaccination of primed animals with the same threshold PA levels was effective for memory activation, yielding a robust and rapid secondary response. A challenge with a lethal dose (40 50% lethal doses; 2,000 spores) of spores after the booster vaccinations indicated that animals were not protected at days 2, 4, and 6 postboosting. Protection was achieved only from the 8th day postboosting, concomitant with the detection of protective levels of neutralizing antibody titers in the circulation. The practical implications from the studies reported herein are that, as expected, the protective capacity of memory depends on the PA dose used for the primary immunization and that the effectiveness of booster immunizations for the postexposure treatment of anthrax may be very limited when no detectable antibodies are present in primed animals prior to Bacillus anthracis spore exposure. Therefore, to allow for the establishment of memory-dependent protection prior to the expected onset of disease, booster immunizations should not be used without concomitant antimicrobial treatment in postexposure scenarios.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155654      PMCID: PMC415724          DOI: 10.1128/IAI.72.6.3471-3477.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Bioterrorism before and after September 11.

Authors:  R M Atlas
Journal:  Crit Rev Microbiol       Date:  2001       Impact factor: 7.624

2.  Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production.

Authors:  F C BELTON; R E STRANGE
Journal:  Br J Exp Pathol       Date:  1954-04

Review 3.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

4.  Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells.

Authors:  Y Singh; S H Leppla; R Bhatnagar; A M Friedlander
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

5.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.

Authors:  Phillip R Pittman; Dallas Hack; Joseph Mangiafico; Paul Gibbs; Kelly T McKee; Arthur M Friedlander; Maria H Sjogren
Journal:  Vaccine       Date:  2002-05-15       Impact factor: 3.641

7.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

8.  Anthrax protective antigen forms oligomers during intoxication of mammalian cells.

Authors:  J C Milne; D Furlong; P C Hanna; J S Wall; R J Collier
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

9.  Purification and properties of in vitro-produced anthrax toxin components.

Authors:  D C Fish; B G Mahlandt; J P Dobbs; R E Lincoln
Journal:  J Bacteriol       Date:  1968-03       Impact factor: 3.490

10.  Contribution of individual toxin components to virulence of Bacillus anthracis.

Authors:  C Pezard; P Berche; M Mock
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

View more
  23 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.

Authors:  Shay Weiss; David Kobiler; Haim Levy; Hadar Marcus; Avi Pass; Nili Rothschild; Zeev Altboum
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

Authors:  Ashley L St John; Cheryl Y Chan; Herman F Staats; Kam W Leong; Soman N Abraham
Journal:  Nat Mater       Date:  2012-01-22       Impact factor: 43.841

4.  Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine.

Authors:  Kun Liu; Ying Yin; Jun Zhang; Xiaodong Zai; Ruihua Li; Hao Ma; Junjie Xu; Junjie Shan; Wei Chen
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

5.  Development of a guinea pig immune response-related microarray and its use to define the host response following Mycobacterium bovis BCG vaccination.

Authors:  Julia A Tree; Michael J Elmore; Sajid Javed; Ann Williams; Philip D Marsh
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

6.  Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.

Authors:  R Aloni-Grinstein; O Gat; Z Altboum; B Velan; S Cohen; A Shafferman
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

7.  The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells.

Authors:  William W Kwok; Junbao Yang; Eddie James; John Bui; Laurie Huston; Andrew R Wiesen; Michelle Roti
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

8.  Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen.

Authors:  Jon Oscherwitz; Fen Yu; Jana L Jacobs; Te-Hui Liu; Philip R Johnson; Kemp B Cease
Journal:  Infect Immun       Date:  2009-06-01       Impact factor: 3.441

9.  Frequent and seasonally variable sublethal anthrax infections are accompanied by short-lived immunity in an endemic system.

Authors:  Carrie A Cizauskas; Steven E Bellan; Wendy C Turner; Russell E Vance; Wayne M Getz
Journal:  J Anim Ecol       Date:  2014-03-14       Impact factor: 5.091

10.  Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Authors:  Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Bat-El Lachmi; Adva Mechaly; Shaul Reuveny; Orit Gat; Ohad Mazor; Arie Ordentlich
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.